John Walter Hanna Jr. - 16 Jul 2026 Form 4 Insider Report for CareDx, Inc. (CDNA)

Reporting relationship: President and CEO, Director
Issuer ticker: CDNA
Reported as of: 16 Jul 2026
Net transaction value: -$4,458,637
SEC form: 4
Accepted by SEC: 17 Jul 2026, 16:23:30 UTC
Prior SEC filing: 06 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ John Walter Hanna, Jr.

Key filing fact

John Walter Hanna Jr. filed Form 4 for CareDx, Inc. (CDNA) on 17 Jul 2026.

Key facts

This page summarizes John Walter Hanna Jr.'s Form 4 filing for CareDx, Inc. (CDNA).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jul 2026, 16:23.

Change

Previous filing in this sequence was filed on 06 Jul 2026.
Current net transaction value: -$4,458,637.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001781127 Primary reporting owner

Hanna John Walter JR

Relationship: President and CEO, Director
Address: C/O CAREDX, INC., 8000 MARINA BOULEVARD, 4TH FLOOR, BRISBANE
Signature: /s/ John Walter Hanna, Jr.
Signature date: 17 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CDNA transaction

Common Stock

Options Exercise

Transaction value
Shares: +118,000
Change %: +18%
Price: $8.20^*
Shares after: 771,448
Date: 16 Jul 2026
Ownership: Direct

CDNA transaction

Common Stock

Sale

Transaction value: $1,805,705
Shares: -50,000
Change %: -6.5%
Price: $36.11
Shares after: 721,448
Date: 16 Jul 2026
Ownership: Direct
Footnotes: F1, F2

CDNA transaction

Common Stock

Sale

Transaction value: $2,652,932
Shares: -68,000
Change %: -9.4%
Price: $39.01
Shares after: 653,448
Date: 16 Jul 2026
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CDNA transaction Derivative

Employee Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -118,000
Change %: -19%
Price: $0.000000^*
Shares after: 512,706
Date: 16 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 118,000
Exercise price: $8.20
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

Footnote F2

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.56 to $36.51 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

1/4th of the shares subject to the option shall vest on April 15, 2025 and 1/48th of the shares subject to the option shall vest monthly thereafter.